Galderma Group (GALD) Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GALD from our risk checks.
GALD Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 154.95 |
| 52 Week High | CHF 188.25 |
| 52 Week Low | CHF 130.20 |
| Beta | -0.11 |
| 1 Month Change | -10.43% |
| 3 Month Change | -10.41% |
| 1 Year Change | 6.28% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 142.11% |
Recent News & Updates
Narrative Update • Sep 03
GALD: Elevated P E Will Likely Struggle If Injectable Aesthetics Disappoint
Analysts have trimmed their fair value estimate for Galderma Group to CHF 137.52 from CHF 141.58, while citing higher price targets such as CHF 210 and expectations around Nemluvio and injectable aesthetics as key drivers of their updated view. Analyst Commentary Recent research on Galderma Group highlights a wide range of price targets, with some large firms pointing to levels between CHF 175 and CHF 210.Narrative Update • Aug 13
GALD: Rich P E And Nemluvio Dependence Will Likely Cap Future Upside
Analysts have raised their average price targets for Galderma Group toward the upper end of the recent CHF 175 to CHF 210 range, citing stronger conviction in Nemluvio and injectable aesthetics. They also updated fair value assumptions from about CHF 132 to roughly CHF 142 per share, reflecting slightly higher margin expectations and a lower future P/E that offsets more moderate revenue growth forecasts.
Narrative Update • Jul 30
GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction
Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.Recent updates
Narrative Update • Sep 03
GALD: Elevated P E Will Likely Struggle If Injectable Aesthetics Disappoint
Analysts have trimmed their fair value estimate for Galderma Group to CHF 137.52 from CHF 141.58, while citing higher price targets such as CHF 210 and expectations around Nemluvio and injectable aesthetics as key drivers of their updated view. Analyst Commentary Recent research on Galderma Group highlights a wide range of price targets, with some large firms pointing to levels between CHF 175 and CHF 210.Narrative Update • Aug 13
GALD: Rich P E And Nemluvio Dependence Will Likely Cap Future Upside
Analysts have raised their average price targets for Galderma Group toward the upper end of the recent CHF 175 to CHF 210 range, citing stronger conviction in Nemluvio and injectable aesthetics. They also updated fair value assumptions from about CHF 132 to roughly CHF 142 per share, reflecting slightly higher margin expectations and a lower future P/E that offsets more moderate revenue growth forecasts.Narrative Update • Jul 30
GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction
Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.Narrative Update • Jul 16
GALD: FDA Manufacturing Setbacks And Rich P/E Will Likely Cap Future Upside
Galderma Group's analyst price target is updated to CHF 131.68 from CHF 125.65 as analysts factor in revised fair value assumptions, including adjusted revenue growth, profit margin, and future P/E inputs, alongside recent Street target increases to as high as CHF 175. Analyst Commentary Recent Street research on Galderma Group points to a mixed tone.
Narrative Update • Jul 01
GALD: Higher CHF Sentiment Will Test Acne Franchise Concentration Risk
Analysts have raised the Galderma Group fair value estimate by about CHF 5 to CHF 188 per share, citing updated Street research with higher CHF price targets from several major banks as support for the revised view. Analyst Commentary Recent Street research on Galderma Group has centered on a series of upward price target revisions in CHF terms, which analysts link to their reassessment of the company’s execution and potential growth options.Narrative Update • Jun 17
GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside
Analysts have raised the Galderma Group price target by CHF 5 to CHF 125.65, citing updated assumptions on fair value, revenue growth, profit margins and forward P/E that are consistent with a recent series of target increases from major banks. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets, framed around updated assumptions for earnings quality, revenue mix and P/E levels.Narrative Update • Jun 03
GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk
Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.Narrative Update • May 13
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Concentration Risk
Analysts have nudged their average price target for Galderma higher by around CHF 5 to reflect updated assumptions for revenue growth, profit margins and longer term P/E expectations, following a series of recent target increases from firms such as Morgan Stanley, Citi, RBC Capital, Berenberg, H.C. Wainwright and Barclays. Analyst Commentary Recent research on Galderma Group has been active, with several firms updating their views and price targets.Narrative Update • Apr 28
GALD: Higher Fair Value View Will Support Future Re Rating Conviction
Analysts have increased the Galderma Group fair value estimate by about CHF 48, from roughly CHF 192 to around CHF 240. They cite recent price target increases across several firms, along with support from product driven growth assumptions and a higher future P/E multiple.Narrative Update • Apr 14
GALD: Elevated Expectations For Dermatology Franchise Will Likely Cap Future Share Upside
Analysts have raised the Galderma Group price target by CHF 7 to reflect updated expectations for revenue growth, profit margin and future P/E, supported by a series of recent CHF-based target increases from several research houses. Analyst Commentary Recent research updates show a cluster of higher CHF based price targets for Galderma Group, with several firms revising their assumptions around growth, margins and P/E multiples.Narrative Update • Mar 31
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Execution Risk
The updated analyst price target for Galderma Group moves higher to reflect Street research that cites support from products like Nemluvio, tighter profit margin assumptions, a slightly adjusted discount rate, and a modestly lower future P/E expectation across recent CHF 155 to CHF 260 target revisions. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into a CHF 155 to CHF 260 range, which signals higher conviction in Galderma Group's valuation support at current levels.Narrative Update • Mar 17
GALD: High Expectations For Key Therapies Will Likely Restrain Future Share Returns
Narrative Update on Galderma Group The updated analyst price target for Galderma Group has moved higher in the latest model, aligning with recent Street target increases to CHF 155, CHF 200 and CHF 260, as analysts highlight support from products such as Nemluvio and adjustments to growth and margin assumptions. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets in the CHF 155 to CHF 260 range, with different attitudes on how much upside may be left.Narrative Update • Mar 03
GALD: Elevated Growth Assumptions Will Likely Pressure Shares Despite Raised Outlook
Analysts have raised their Galderma Group price target to CHF 195 from CHF 155, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E that modestly reduce estimated fair value to CHF 110.71 from CHF 111.24. Analyst Commentary The latest price target move to CHF 195 sits well above the estimated fair value of CHF 110.71, which signals that some analysts are embedding optimistic assumptions on growth and profitability.Narrative Update • Feb 16
GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction
Analysts have raised their price target on Galderma Group to CHF 195 from CHF 155, reflecting updated views on revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent research points to a more constructive stance on Galderma Group, with bullish analysts lifting their price targets and expressing increased confidence in the company’s execution and valuation framework.Narrative Update • Feb 02
GALD: Higher Future P/E Assumptions Will Likely Pressure Shares Forward
Analysts have lifted their price target on Galderma Group to CHF 195 from CHF 155, citing updated assumptions that include higher fair value estimates, a slightly adjusted discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. Analyst Commentary The move to a CHF 195 price target is framed around updated valuation work, with higher assumed fair value, a revised discount rate, and adjusted revenue and margin assumptions.Narrative Update • Jan 19
GALD: Raised Growth Outlook And L’Oréal Stake Increase Will Support Re Rating
Analysts have raised their blended price target range for Galderma Group to approximately CHF 195 to CHF 200 from about CHF 140 to CHF 165, citing updated fair value estimates, revised assumptions for revenue growth and profit margins, as well as a higher projected P/E multiple. Analyst Commentary Recent Street research points to a more constructive stance on Galderma Group, with several bullish analysts lifting their price targets into the CHF 140 to CHF 195 range.Narrative Update • Jan 05
GALD: Rising Market Optimism Will Meet Execution Risk And Fairly Balanced Prospects
Analysts have made a marginal trim to their fair value estimate for Galderma Group to approximately CHF 159.55 per share, even as Street price targets have moved higher into a CHF 140 to CHF 182 range. This reflects updated views on the stock's P/E assumptions and recent research from multiple banks.Narrative Update • Dec 14
GALD: Rising Market Optimism Will Meet Execution And Competitive Challenges Ahead
Analysts have nudged their blended price target for Galderma Group higher by approximately CHF 6, reflecting increased confidence in the companys faster than previously expected revenue growth, improving profit margins, and a slightly richer forward price-to-earnings multiple supported by a series of recent target hikes across the Street. Analyst Commentary Recent target hikes from multiple firms underscore a constructive stance on Galderma Group’s medium term outlook, with bullish analysts pointing to accelerating top line momentum and improving profitability as key drivers of upside to current valuation.Narrative Update • Nov 30
GALD: Upward Momentum In Pricing Will Face Competitive And Execution Risks Ahead
Galderma Group's fair value estimate has been raised from CHF 150.37 to CHF 153.80. This reflects analysts' positive outlook supported by a series of recent upward price target revisions in light of expectations of continued revenue growth and stable profitability.Narrative Update • Nov 16
GALD: Momentum In Product Approvals And Expansion Will Face Execution Challenges
Galderma Group’s analyst price target has been revised upward from CHF 149.91 to CHF 150.37. This reflects positive analyst sentiment, driven by higher recent target increases and confidence in the company’s growth prospects.Narrative Update • Oct 31
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.Analysis Article • Oct 29
Is Galderma Group AG (VTX:GALD) Trading At A 40% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Galderma Group fair value estimate is CHF239 Current share...Narrative Update • Oct 17
Global Aesthetics And Aging Trends Will Drive Expansion
The analyst price target for Galderma Group has been raised, with new estimates increasing from CHF 140.69 to CHF 142.41. This change reflects analysts' optimism on the company's outlook amid steady growth expectations and supportive recent research updates.Narrative Update • Aug 27
Global Aesthetics And Aging Trends Will Drive Expansion
Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.New Narrative • May 12
Nemluvio Launch And Global Expansion Will Shape Therapeutic Dermatology Markets
Launch of Nemluvio and international expansion in China and India are expected to significantly boost revenue growth and market share.Shareholder Returns
| GALD | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -2.3% | -7.5% | -3.5% |
| 1Y | 6.3% | 21.4% | 11.0% |
Return vs Industry: GALD underperformed the Swiss Pharmaceuticals industry which returned 21.4% over the past year.
Return vs Market: GALD underperformed the Swiss Market which returned 11% over the past year.
Price Volatility
| GALD volatility | |
|---|---|
| GALD Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: GALD has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: GALD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 7,676 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| GALD fundamental statistics | |
|---|---|
| Market cap | CHF 36.13b |
| Earnings (TTM) | CHF 704.75m |
| Revenue (TTM) | CHF 4.84b |
51.3x
P/E Ratio7.5x
P/S RatioIs GALD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALD income statement (TTM) | |
|---|---|
| Revenue | US$5.92b |
| Cost of Revenue | US$1.81b |
| Gross Profit | US$4.11b |
| Other Expenses | US$3.25b |
| Earnings | US$863.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.70 |
| Gross Margin | 69.37% |
| Net Profit Margin | 14.57% |
| Debt/Equity Ratio | 30.8% |
How did GALD perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 02:38 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galderma Group AG is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yihan Li | Barclays |
| James Gordon | Barclays |
| Fulvio Cazzol | Berenberg |